Expert Interview
Investigating the potential of liraglutide, a GLP-1 agonist from Novo Nordisk as a treatment for obesity in children younger than 12 years of age
Ticker(s): NVOInstitution: Children's Minnesota
- Pediatric Endocrinologist at the McNeely Pediatric Diabetes Center and Endocrine Clinic at Children's Minnesota
- Cares for children with general endocrine issues such as pubertal disorders, thyroid dysfunction, growth disorders, and diabetes
- Areas of interest include neuro-endocrine disorders, such as radiation induced hypopituitarism and hypothalamic damage, and hypothalamic obesity
- Participates in clinical research in Prader Willi syndrome, obesity, and growth disorders
Can you provide some background information about yourself, your expertise, and your current practice setting?
Added By: dami_adminHow many pediatric patients with obesity do you currently see on a monthly basis?
Added By: dami_adminWhat is your opinion on the potential of the GLP-1 class, particularly liraglutide, for the treatment of pediatric obesity?
Added By: dami_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
